Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in patients with autoimmune hepatitis (AIH)

Trial Profile

Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in patients with autoimmune hepatitis (AIH)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Denosumab (Primary)
  • Indications Corticosteroid-induced osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 01 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top